Ovid Therapeutics Inc. announced positive topline results from its Phase 1 clinical study evaluating OV329, a next-generation GABA-aminotransferase inhibitor, in healthy volunteers. The study assessed safety, tolerability, pharmacokinetics, and pharmacodynamics of OV329, which is being developed for drug-resistant epilepsies. According to the company, OV329 demonstrated a favorable safety and tolerability profile, including clean ocular safety, and showed consistent biomarker results across validated measures. Ovid plans to advance OV329 into a Phase 2a randomized, placebo-controlled trial in adult patients with drug-resistant focal onset seizures, with initiation anticipated in the second quarter of 2026 and completion expected by mid-2027. Further data from the Phase 1 study will be presented at an upcoming medical meeting. Additionally, Ovid is progressing its portfolio of potassium-chloride cotransporter 2 (KCC2) direct activator programs, with several regulatory and clinical milestones for both intravenous and oral KCC2 candidates anticipated over the next 12 months. The company also intends to complete a final enabling study to support regulatory filings for its first oral KCC2 direct activator, OV4071, in early 2026.